April 30, 2017 3:25 PM ET


Company Overview of InCarda Therapeutics, Inc.

Company Overview

InCarda Therapeutics, Inc. develops transformative therapies that enable patients to use in the first moments of acute cardiovascular symptoms. The company develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. InCarda Therapeutics, Inc. was formerly known as Pleiades Cardio-Therapeutics, Inc. The company was incorporated in 2009 and is based in San Francisco, California.

150 Post Street

Suite 650

San Francisco, CA 94108

United States

Founded in 2009





Key Executives for InCarda Therapeutics, Inc.

Chief Executive Officer and President
Co-Founder and Executive Chairman
Age: 68
Co-Founder and Chief Operating Officer
Co-Founder and Chief Scientific Officer
Co-Founder and Chief Medical Officer for Consulting
Compensation as of Fiscal Year 2016.

InCarda Therapeutics, Inc. Key Developments

InCarda Therapeutics, Inc. Presents at 9th Annual Conference Biotech Showcase, Jan-09-2017

InCarda Therapeutics, Inc. Presents at 9th Annual Conference Biotech Showcase, Jan-09-2017 . Venue: HILTON SAN FRANCISCO UNION SQUARE, 333 O'Farrell Street, San Francisco, CA 94102, United States.

InCarda Therapeutics, Inc. Initiates Phase 1 Clinical Trial for Its Lead Product to Treat Recent Onset Atrial Fibrillation

InCarda Therapeutics, Inc. announced that it has initiated a Phase 1 clinical trial for its lead product intended to treat recent onset atrial fibrillation. The single-center trial will evaluate the safety and tolerability of inhaled flecainide in a randomized, double-blind, placebo-controlled design consisting of single ascending doses of inhaled active solution, or inhaled placebo solution, in multiple cohorts of healthy volunteers. This study is being conducted at CMAX, a division of IDT Australia.

InCarda Therapeutics, Inc. Elects Norbert Bischofberger to Board of Directors

InCarda Therapeutics, Inc. announced the election of Norbert Bischofberger to the company's board of directors. Dr. Bischofberger has spent over 25 years at Gilead Sciences, where he currently serves as the company's chief scientific officer and executive vice president of research and development. Dr. Norbert Bischofberger has served at Gilead Sciences since 1990 and is currently the company's chief scientific officer and executive vice president of research and development.

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact InCarda Therapeutics, Inc., please visit incardatherapeutics.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.